Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the China National Drug Administration, agreeing to conduct phase III clinical trials for prostate cancer with deuterium enzalutamide softgels. Clinical trial protocol name: A randomized, double-blind, placebo-controlled phase III study comparing deuterium enzalutamide combined with androgen deprivation treatment (ADT) and placebo combined with ADT in patients with high-risk biochemical recurrence (BCR) prostate cancer.

The new indication is combined with androgen deprivation therapy (ADT) for the treatment of high-risk biochemical recurrence (BCR) prostate cancer. The aim is to target patients who have recurred after early radical treatment for prostate cancer, slow the progression of the patient's disease, improve long-term survival benefits, meet unmet clinical needs, and enhance future product sales space.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.